Hologic Q4 sales boom on diagnostics revenues

By LabPulse.com staff writers

November 5, 2020 -- Booming revenues in its Molecular Diagnostics segment due to the COVID-19 pandemic helped Hologic post a 55.6% increase in sales for its fourth quarter. The company also swung into the black compared with a net loss in the same period the year before.

For the fourth quarter (end-September 26), Hologic recorded revenues of $1.3 billion compared with $865.8 million in the same quarter last year. The increase was bolstered by the company's Worldwide Molecular Diagnostics revenue, which increased by 375.8% to $818.9 million, due to demand for its SARS-CoV-2 assays.

Net income for the quarter was $493.6 million, compared with a net loss in 2019 of $123.5 million.

For the year, Hologic posted revenue of $3.776 billion, up 12% compared with $3.367 billion in 2019. The company's net income for the year was $1.1 billion, compared with a $203.6 million net loss last year.

Hologic scores $119M COVID-19 testing contract
The U.S. government has awarded a $119 million contract to Hologic to expand its production capacity for COVID-19 molecular tests.
Hologic debuts pooling protocol for COVID-19 tests
Hologic has validated the use of its Aptima and Panther Fusion molecular diagnostic COVID-19 assays with pooled patient samples and has also applied for...
Molecular diagnostics sales surge in Hologic's Q3
A strong surge in sales of its molecular diagnostics products helped Hologic offset declines in other areas of the company's business in its third fiscal...
FDA gives Hologic EUA for SARS-CoV-2 test
The U.S. Food and Drug Administration (FDA) gave Hologic emergency use authorization (EUA) for its Aptima SARS-CoV-2 molecular test for detection of the...
Hologic debuts research-use-only SARS-CoV-2 test
Hologic has launched a research-use-only version of a new molecular assay that can detect SARS-CoV-2 and which is expected to dramatically increase testing...

Copyright © 2020 LabPulse.com

Last Updated ls 11/5/2020 3:43:56 PM